ArticleJournal of neuro-oncology2012
Use of recombinant tissue plasminogen activator in cancer patients with acute stroke.
Article in Journal of neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Intravenous thrombolysis in the context of stroke and cancer.Journal of thrombosis and thrombolysis · 2025Review
- A Single-Center Experience of Mechanical Thrombectomy for Cancer-Associated Ischemic Stroke.Journal of neuroendovascular therapy · 2024Article
- Effectiveness of mechanical thrombectomy in cancer-related stroke and associated factors with unfavorable outcome.BMC neurology · 2021Article
- Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding.European stroke journal · 2020Article
- Efficacy and safety of intravenous thrombolysis for acute ischemic stroke in cancer patients: a systemic review and meta-analysis.American journal of translational research · 2020Review
- Intra-arterial thrombectomy for acute ischaemic stroke patients with active cancer.Journal of neurology · 2019Article
- Temporal Trends in the Use of Acute Recanalization Therapies for Ischemic Stroke in Patients with Cancer.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2019Article
- Cancer-associated stroke: Pathophysiology, detection and management (Review).International journal of oncology · 2019Review
- Clinical features of systemic cancer patients with acute cerebral infarction and its underlying pathogenesis.International journal of clinical and experimental medicine · 2015Article
- Intravenous tissue plasminogen activator for an ischemic stroke with occult double primary cancer.Case reports in neurology · 2014Article
- Intracranial hemorrhage in patients with cancer.Current atherosclerosis reports · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with cancer may be at increased risk for stroke, especially of cardioembolic and large vessel origin. Some clinicians are reluctant to use recombinant tissue plasminogen activator (rTPA) in the cancer population due to safety concerns. We conducted a retrospective review of patients who received rTPA for acute stroke at an academic cancer center. We report six patients with cancer treated with rTPA at our institution, four of whom had early neurologic recovery. Only one of our six patients suffered minor bleeding as a complication of rTPA. Acute stroke in patients with cancer may be treated with rTPA, and active cancer should not be considered an absolute contraindication to rTPA use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.